FDA Action-Item List Shows Plans To Revamp De Novo, Combo Product, QSR Regs, And More
Executive Summary
Planned US FDA actions on the spring 2020 Agency Rule List show expected rules around de novo applications, and combination product classification and appeals – as well as the long-awaited Quality System Regulation overhaul.
You may also be interested in...
FDA Sets (Another) Deadline For Releasing Draft Harmonized Quality System Regulation
October 2020 is the new in-house target date for the US agency to release a draft of its revised QSR, which will be harmonized with international quality systems standard ISO 13485.
Minding The Middle: FDA Fleshes Out De Novo Regs As The Program Expands
A new proposed rule on the de novo classification process does not advance any major policy reforms, but its release underscores the growing popularity of the regulatory pathway that provides flexibility for US FDA and industry in the space between 510(k)s and PMAs.
US Combo Product Designation Appeal Process Refined In Proposed Rule
In an overhaul of a regulation that sets out how US FDA designates combo products to product centers, the agency is proposing to update its policies so they align with current practices and mandates. FDA is also specifically proposing to streamline a designation appeal process that it says has been a burden for all parties.